(NASDAQ: SEPN) Septerna's forecast annual revenue growth rate of 982.58% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 245.56%, and it is also forecast to beat the US market's average forecast revenue growth rate of 11.89%.
Septerna's revenue in 2025 is $726,000.On average, 1 Wall Street analysts forecast SEPN's revenue for 2025 to be $6,257,077,846, with the lowest SEPN revenue forecast at $6,257,077,846, and the highest SEPN revenue forecast at $6,257,077,846. On average, 2 Wall Street analysts forecast SEPN's revenue for 2026 to be $3,343,885,125, with the lowest SEPN revenue forecast at $2,452,182,425, and the highest SEPN revenue forecast at $4,235,587,825.
In 2027, SEPN is forecast to generate $2,229,256,750 in revenue, with the lowest revenue forecast at $2,229,256,750 and the highest revenue forecast at $2,229,256,750.